VIVO News and Press, Meridian Bioscience Inc. From 05/17/22

Meridian Bioscience Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays Meridian Bioscience Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for ...

With the Dow Jones Composite average down more than 9% and the Nasdaq Composite down more than 25% this year, it's good to know that not all stocks are suffering. Williams Companies (NYSE: WMB) , Meridian Bioscience (NASDAQ: VIVO) , and ConocoPhillips (NYSE...

The following slide deck was published by Meridian Bioscience, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Meridian Bioscience, Inc. 2022 Q2 - Results - Earnings Call Presentation

Meridian Bioscience, Inc. (VIVO) Q2 2022 Earnings Conference Call May 6, 2022 10:00 am ET Corporate Participants Charlie Wood - Vice President of Investor Relations Jack Kenny - Chief Executive Officer Andy Kitzmiller - Chief Financial Officer Conference Call Participants Dustin Scaringe - Wi...

Meridian Bioscience press release (NASDAQ:VIVO): FQ2 Non-GAAP EPS of $0.66 beats by $0.19. Revenue of $111.23M (+30.5% Y/Y) beats by $11.68M. The company is raising FY2022 outlook: Net revenue: $330M to $345M vs. consensus of $337.62M; Adjusted Operating Margin: 22.5% to 23.5%; Adjusted ...

MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS PR Newswire CINCINNATI , May 6, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2022 ...

Meridian Bioscience (NASDAQ:VIVO) has acquired, through its subsidiary Meridian Life Science substantially all of the assets of EUPROTEIN. The transaction closed on April 30, 2022. EUPROTEIN offers custom development and production of high-quality bioresearch reagents, with a particular ...

Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities PR Newswire CINCINNATI, Ohio , May 2, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw...

Meridian Bioscience (NASDAQ:VIVO) provided preliminary net revenues for FQ2 are expected to be between $109M and $113M, above company's expectations and a record for the company. Consensus revenue expectation for FQ2 is $83.3M. Individually, both of the company's segments are also e...

Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter PR Newswire CINCINNATI , April 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and li...